Related Experiment Videos
Fixed duration MDT in paucibacillary leprosy
1Department of Dermatology, Christian Medical College & Hospital, Vellore, South India.
Abstract:
The World Health Organization (WHO) has recommended a fixed duration of multidrug therapy (MDT) for paucibacillary leprosy which is currently widely implemented in India. A clinico-pathological study was initiated in 1984 to assess the efficacy of this regimen. The clinical and histological responses of the patients to MDT were assessed at the end of 6 months, when their treatment was stopped, and at 2 1/2 years, when they were released from surveillance, and compared with the responses of a matched patient group to conventional dapsone (DDS) monotherapy during the same period. Of 28 patients who completed the MDT schedule, there was less than 60% improvement in 33% of them when treatment was stopped at the end of 6 months and in 20% of them at the end of 2 1/2 years. Of 26 patients receiving DDS monotherapy, 37% showed less than 60% improvement at the end of 6 months but only 8.8% had less than 60% improvement at 2 1/2 years. It is concluded that MDT for paucibacillary leprosy as recommended by WHO may not have a major advantage over DDS monotherapy, since about 20% of those patients on MDT continue to have evidence of active disease when discharged from surveillance.
Insights
Multidrug therapy (MDT) for paucibacillary leprosy shows limited advantage over dapsone monotherapy. Many patients on MDT still exhibit active disease signs post-treatment, indicating potential limitations in current WHO recommendations.
Area of Science:
- Dermatology
- Infectious Diseases
- Clinical Pathology
Background:
- The World Health Organization (WHO) established fixed-duration multidrug therapy (MDT) for paucibacillary leprosy, widely adopted in India.
- A comparative clinico-pathological study was conducted to evaluate MDT's efficacy against conventional dapsone (DDS) monotherapy.
Purpose of the Study:
- To assess the clinical and histological efficacy of WHO-recommended MDT for paucibacillary leprosy.
- To compare the treatment outcomes of MDT with dapsone monotherapy.
Main Methods:
- A clinico-pathological study initiated in 1984 compared MDT with dapsone monotherapy.
- Patient responses were assessed at 6 months (treatment cessation) and 2.5 years (surveillance release).
- Histological and clinical improvements were evaluated for both treatment groups.
Main Results:
- At 2.5 years, 20% of patients on MDT showed less than 60% improvement, indicating persistent active disease.
- In contrast, only 8.8% of patients on dapsone monotherapy had less than 60% improvement at 2.5 years.
- At 6 months, 33% of MDT patients and 37% of dapsone patients had less than 60% improvement.
Conclusions:
- WHO-recommended MDT for paucibacillary leprosy may not offer significant advantages over dapsone monotherapy.
- A notable percentage of patients on MDT continue to show signs of active leprosy upon completion of surveillance.
- Further evaluation of leprosy treatment regimens may be warranted to improve long-term outcomes.